Product Name :
BRD3308
Description:
BRD3308 is a highly selective HDAC3 inhibitor with an IC50 of 54 nM. BRD3308 is 23-fold selectivity for HDAC3 over HDAC1 (IC50 of 1.26 μM) or HDAC2 (IC50 of 1.34 μM). BRD3308 suppresses pancreatic β-cell apoptosis induced by inflammatory cytokines or glucolipotoxic stress, and increases functional insulin release. BRD3308 activates HIV-1 transcription and disrupts HIV-1 latency.
CAS:
1550053-02-5
Molecular Weight:
287.29
Formula:
C15H14FN3O2
Chemical Name:
N-(2-amino-4-fluorophenyl)-4-acetamidobenzamide
Smiles :
CC(=O)NC1C=CC(=CC=1)C(=O)NC1=CC=C(F)C=C1N
InChiKey:
RRJDFENBXIEAPD-UHFFFAOYSA-N
InChi :
InChI=1S/C15H14FN3O2/c1-9(20)18-12-5-2-10(3-6-12)15(21)19-14-7-4-11(16)8-13(14)17/h2-8H,17H2,1H3,(H,18,20)(H,19,21)
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
BRD3308 is a highly selective HDAC3 inhibitor with an IC50 of 54 nM. BRD3308 is 23-fold selectivity for HDAC3 over HDAC1 (IC50 of 1.26 μM) or HDAC2 (IC50 of 1.34 μM). BRD3308 suppresses pancreatic β-cell apoptosis induced by inflammatory cytokines or glucolipotoxic stress, and increases functional insulin release. BRD3308 activates HIV-1 transcription and disrupts HIV-1 latency.|Product information|CAS Number: 1550053-02-5|Molecular Weight: 287.29|Formula: C15H14FN3O2|Chemical Name: N-(2-amino-4-fluorophenyl)-4-acetamidobenzamide|Smiles: CC(=O)NC1C=CC(=CC=1)C(=O)NC1=CC=C(F)C=C1N|InChiKey: RRJDFENBXIEAPD-UHFFFAOYSA-N|InChi: InChI=1S/C15H14FN3O2/c1-9(20)18-12-5-2-10(3-6-12)15(21)19-14-7-4-11(16)8-13(14)17/h2-8H,17H2,1H3,(H,18,20)(H,19,21)|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 250 mg/mL (870.{{Glycocholic acid} web|{Glycocholic acid} Metabolic Enzyme/Protease|{Glycocholic acid} Biological Activity|{Glycocholic acid} Data Sheet|{Glycocholic acid} custom synthesis|{Glycocholic acid} Cancer} 20 mM; Need ultrasonic).{{DAPT} web|{DAPT} Autophagy|{DAPT} Purity & Documentation|{DAPT} Purity|{DAPT} custom synthesis|{DAPT} Epigenetic Reader Domain} |Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.PMID:29844565 |Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|BRD3308 (5-30 µM; 6-24 hours) treatment increases HIV-1 expression in the 2D10 cell line. BRD3308 (15 µM; overnight) is able to induce outgrowth of HIV-1 from latently infected cells ex vivo in resting CD4+ T cells.BRD3308 inhibits HDAC1, HDAC2 and HDAC3 with Ki values of 5.1 μM, 6.3 μM and 29 nM, respectively.|In Vivo:|BRD3308 (5 mg/kg; intraperitoneal injection; every second day; male Zucker Diabetic Fatty rats) treatment reduces hyperglycaemia and increases insulin secretion in a rat model of type 2 diabetes. At the end of the hyperglycaemic clamp, circulating insulin levels are significantly higher in BRD3308-treated rats. Pancreatic insulin staining and contents are also significantly higher. BRD3308 preserves the functional β-cell mass against glucolipotoxicity in vivo.|Products are for research use only. Not for human use.|
